Stock Events

Stock Events

Immatics N.V 

€5.68
51
+€0.00+0.09%Friday 16:30

Statistics

Day High
5.58
Day Low
5.56
52W High
7.17
52W Low
5.56
Volume
-
Avg. Volume
-
Mkt Cap
863.88M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 17Expected
Q2 2026
Next
-0.46
-0.44
-0.43
-0.41
Expected EPS
-0.459367706166992
Actual EPS
N/A

Financials

-407.01%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
48.27MRevenue
-196.45MNet Income

Analyst Ratings

$15.18Average Price Target
The highest estimate is ⁦18.97⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4A3.XETRA. It's not an investment recommendation.
Amazon
6
AMZN
NVIDIA
6
NVDA
Broadcom
6
AVGO
Plug Power
6
PLUG

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap211.7B
Gilead Sciences, Inc. has a strong presence in cell therapy for cancer, competing in the broader oncology market that Immatics targets.
Novartis
NVS
Mkt Cap303.67B
Novartis AG has been a pioneer in CAR-T cell therapy for cancer, representing a major competitor in the cell therapy space where Immatics operates.
Allogene Therapeutics
ALLO
Mkt Cap407.68M
Allogene Therapeutics, Inc. works on allogeneic CAR-T therapies for cancer, competing in the innovative cell therapy market alongside Immatics.
Pfizer
PFE
Mkt Cap173.95B
Pfizer Inc. has investments in cancer therapies, including collaborations on CAR-T and TCR therapies, positioning it as a competitor in the oncology space.
Merck
MRK
Mkt Cap368.89B
Merck & Co., Inc. is heavily involved in cancer treatment research and development, including immunotherapies that compete with Immatics' approach to cancer treatment.

About

Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Show More
CEO
Harpreet Singh
Employees
407
Country
Germany
ISIN
NL0015285941
WKN
000A2P72S

Listings

MU
DE
4A3.MU
BOATS
BOATS
IMTX.BOATS
F
DE
4A3.F
XNAS
US
IMTX

0 Comments

Share your thoughts

FAQs

What is Immatics N.V stock price today?▼
The current price of 4A3.XETRA is €5.68 EUR — it has increased by +0.09% in the past 24 hours. Watch Immatics N.V stock price performance more closely on the chart.
What is Immatics N.V stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Immatics N.V stocks are traded under the ticker 4A3.XETRA.
What is Immatics N.V market cap?▼
Today Immatics N.V has the market capitalization of 863.88M
When is the next Immatics N.V earnings date?▼
Immatics N.V is going to release the next earnings report on November 17, 2026.
What were Immatics N.V earnings last quarter?▼
4A3.XETRA earnings for the last quarter are -0.45 EUR per share, whereas the estimation was -0.41 EUR resulting in a -9.48% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Immatics N.V revenue for the last year?▼
Immatics N.V revenue for the last year amounts to 48.27M EUR.
What is Immatics N.V net income for the last year?▼
4A3.XETRA net income for the last year is -196.45M EUR.
How many employees does Immatics N.V have?▼
As of November 8, 2026, the company has 407 employees.
In which sector is Immatics N.V located?▼
Immatics N.V operates in the Health & Wellness sector.
When did Immatics N.V complete a stock split?▼
Immatics N.V has not had any recent stock splits.
Where is Immatics N.V headquartered?▼
Immatics N.V is headquartered in Tübingen, Germany.